Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Prog Retin Eye Res. 2021 Mar 26;85:100967. doi: 10.1016/j.preteyeres.2021.100967

Figure 3.

Figure 3.

Anti-angiogenic effects of MSCs on the cornea through TSG-6-mediated suppression of inflammation.

Corneal neovascularization was induced in mice by suture application, and human BM-derived MSCs transfected with either TSG-6 siRNA (TSG-6 KD MSC) or control scrambled siRNA (control MSC) were intravenously administered (day 0). At day 1, corneal inflammation was evaluated by immunostaining of corneal whole-mounts for CD11b and Ly6G. At day 7, corneal new vessel growth was assessed by clinical observation and immunostaining for CD31 and LYVE-1. Both corneal inflammation and neovascularization were markedly suppressed by control MSCs, but not by TSG-6 KD MSCs or the vehicle (Hank’s balanced salt solution, HBSS).

Reprinted with permission from Molecular Therapy. Song et al., 2018. Mesenchymal Stromal Cells Inhibit Inflammatory Lymphangiogenesis in the Cornea by Suppressing Macrophage in a TSG-6-Dependent Manner. Mol. Ther. 26, 162–172. Copyright © 2017 The American Society of Gene and Cell Therapy.